To participate, please dial one of the following numbers and ask to join the Verona Pharma call: A live webcast will be available on the Events and Presentations link on the Investors page of the ...

Verona is extending Ohtuvayre's life cycle through new formulations and fixed-dose combinations, aiming for cash flow ...

The best performers in the group are the Averill funds. Averill was down 2.9 percent in March but just 0.9 percent in the first quarter. Averill Madison, Suvretta’s longer-biased health care fund, ...

Verona Pharma (VRNA ... Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively More than 3,500 unique prescribers and ...

Ohtuvayre is due to launch in the US in the third quarter of this year, assisted by a $650 million debt facility that Verona agreed a few months ago to build its commercial capabilities.

“2024 was another transformational year for Verona with the approval and US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (“COPD ...

(RTTNews) - Verona Pharma plc (VRNA), Friday announced some strategic changes in its capital structure, increasing the company's financial flexibility and simplifying its balance sheet. The ...

If you need financial support to pay for Ohtuvayre or help understanding your insurance coverage, assistance is available. For example: A program called Verona Pathway Plus is available for Ohtuvayre.

Ohtuvayre (ensifentrine ... talk with your doctor or pharmacist. A program called Verona Pathway Plus may also be available. »Learn more about saving on your prescriptions.

For further information please contact: Verona P Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique ...